Illimis Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 40

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $42M

  • Investors
  • 27

Illimis Therapeutics General Information

Description

Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. The company's platform leverages proprietary protein engineering and molecular design techniques, enabling the biopharmaceutical companies to increase drug candidates with target specificity and improved stability.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2nd and 3rd floors, 18, Heonreung-ro 569-gil, Segok-dong, Unseong Building
  • Gangnam-gu
  • Seoul, 06376
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 2nd and 3rd floors, 18, Heonreung-ro 569-gil, Segok-dong, Unseong Building
  • Gangnam-gu
  • Seoul, 06376
  • South Korea
+82

Illimis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Illimis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 02-Jul-2025 $42M Completed Pre-Clinical Trials
4. Accelerator/Incubator 17-Oct-2023 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 05-Apr-2023 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Oct-2021 $6.97M Completed Startup
1. Seed Round 09-Aug-2021 $6.97M $6.97M Completed Startup
To view Illimis Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Illimis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Illimis Therapeutics Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
A Ventures Venture Capital Minority
Comes Investment Venture Capital Minority
Hana Ventures Corporate Venture Capital Minority
IMM Investment Asset Manager Minority
Industrial Bank of Korea PE/Buyout Minority
You’re viewing 5 of 27 investors. Get the full list »

Illimis Therapeutics FAQs

  • When was Illimis Therapeutics founded?

    Illimis Therapeutics was founded in 2021.

  • Where is Illimis Therapeutics headquartered?

    Illimis Therapeutics is headquartered in Seoul, South Korea.

  • What is the size of Illimis Therapeutics?

    Illimis Therapeutics has 40 total employees.

  • What industry is Illimis Therapeutics in?

    Illimis Therapeutics’s primary industry is Drug Discovery.

  • Is Illimis Therapeutics a private or public company?

    Illimis Therapeutics is a Private company.

  • What is Illimis Therapeutics’s current revenue?

    The current revenue for Illimis Therapeutics is .

  • How much funding has Illimis Therapeutics raised over time?

    Illimis Therapeutics has raised $64.3M.

  • Who are Illimis Therapeutics’s investors?

    A Ventures, Comes Investment, Hana Ventures, IMM Investment, and Industrial Bank of Korea are 5 of 27 investors who have invested in Illimis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process